CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 106 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,041,000 | +28.8% | 334,713 | +40.0% | 0.00% | – |
| Q4 2021 | $808,000 | -6.5% | 239,015 | +1.0% | 0.00% | – |
| Q3 2021 | $864,000 | -7.8% | 236,757 | +10.2% | 0.00% | -100.0% |
| Q2 2021 | $937,000 | -32.1% | 214,940 | -29.3% | 0.00% | 0.0% |
| Q1 2021 | $1,380,000 | -55.8% | 303,879 | -44.1% | 0.00% | -50.0% |
| Q4 2020 | $3,123,000 | -21.7% | 544,025 | -1.3% | 0.00% | -33.3% |
| Q3 2020 | $3,991,000 | +98.3% | 551,258 | -4.4% | 0.00% | +50.0% |
| Q2 2020 | $2,013,000 | +686.3% | 576,718 | +234.1% | 0.00% | – |
| Q1 2020 | $256,000 | +13.8% | 172,640 | +50.2% | 0.00% | – |
| Q4 2019 | $225,000 | -75.8% | 114,977 | -36.7% | 0.00% | -100.0% |
| Q3 2019 | $929,000 | +334.1% | 181,520 | +508.4% | 0.00% | – |
| Q2 2019 | $214,000 | -35.3% | 29,838 | +19.7% | 0.00% | – |
| Q1 2019 | $331,000 | +169.1% | 24,918 | +59.7% | 0.00% | – |
| Q4 2018 | $123,000 | -92.3% | 15,602 | -87.3% | 0.00% | -100.0% |
| Q1 2018 | $1,598,000 | +26.7% | 122,984 | -10.3% | 0.00% | +100.0% |
| Q4 2017 | $1,261,000 | +8.0% | 137,083 | -5.4% | 0.00% | 0.0% |
| Q3 2017 | $1,168,000 | – | 144,905 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |